Search for a trial

A phase IIIB, one year, open label, multicentre, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium injection in subjects with diabetic macular edema (DME)

The primary objective of this study is to further evaluate the safety and tolerability of pegaptanib sodium in subjects with DME.

A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given as individual monotherapies in patients with open angle glaucoma or ocular hypertension

The objective of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to those of tafluprost 0.0015% and timolol 0.5% eye drops given as individual…

Efficacy and cost-effectiveness of toric intraocular lenses in correcting astigmatism in cataract surgery: A Randomised Clinical Trial

The primary objective of this study is to compare the quality of vision following toric IOL implantation and monofocal IOL implantation. The secondary objectives are to compare uncorrected distance vision, spectacle dependence, residual refractive…

A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy
 and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Uveitis Involving the
 Intermediate and/or Posterior Segments of the Eye

The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-,…

A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the efficacy and safety of 0.5 mg ranibizumab in two *treat and extend* treatment algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to diabetes mellitus

Primary objective:To demonstrate that the mean change from baseline in Best Corrected Visual Acuity (BCVA) over a 12 month treatment period obtained with either a 0.5 mg ranibizumab *Treat and Extend* (TE) dosing regimen with adjunctive laser, and/…

VISUAL OUTCOMES AFTER BILATERAL SURGICAL CATARACT PHACOEMULSIFICATION: ACRYSOF® TORIC IOL IMPLANTATION COMPARED TO MONOFOCAL IOL IMPLANTATION.

The objectives of this study are to assess and compare bilateral uncorrected distance visual acuity and distance spectacle independence post bilateral implantation of AcrySof Toric IOLs and monofocal IOLs.

Pilot study to compare straylight perception in pseudophakic subjects with different intraocular lenses

The purpose of this pilot study is to compare the perception of straylight in patients with CE marked multifocal intraocular lenses, measured with 4 different straylight measuring devices..

Clinical and psychosocial determinants influencing treatment effect of occlusion therapy and
rate of recurrence in previously untreated patients with amblyopia between 12 and 40 years of age

The primary purpose is the efficacy of occlusion therapy initiated in patients with untreated amblyopia between twelve and forty years of age. The secondary purposes are rate of recurrence, refractive adaptation, and the social-economic and ethic…

A PROSPECTIVE MULTICENTER CLINICAL TRIAL TO EVALUATE THE SAFETY AND
EFFECTIVENESS OF THE ACUFOCUS* CORNEAL INLAY ACI 7000PDT IMPLANTED
INTRA-STROMALLY FOR MODIFIED MONOVISION IN PRESBYOPIC SUBJECTS

The objective of this study is to evaluate the safety of the AcuFocusTM ACI 7000PDT corneal inlay implanted intra-stromally in emmetropic presbyopes and the effectiveness of the inlay for improvement of near vision.

Safety, Tolerability and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration

To assess the safety, tolerability and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared to Lucentis in patients with exudative AMD

A phase I, open-label study to investigate the absorption, metabolism, excretion, and mass balance of [14C]QLT091001 following single oral dose in healthy male subjects

The study objectives are:- to characterize the biotransformation pathways, the routes and rates of excretion, and total recovery of the 14C-labeled research medication and its radiolabeled metabolites- to characterize the pharmacokinetics (PK) of…

Comparison of the effects of phenylephrine and norepinephrine on hemodynamics and tissue oxygenation in patients undergoing ophthalmic surgery.

Determine whether phenylephrine or norepinephrine has superior haemodynamical effects in ophtalmic surgery

A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of darapladib administered for 3 months to adult subjects with diabetic macular edema with centre involvement (DM2115403)

Primary: efficacy, assessed by best-corrected visual acuity and SD-OCT of 1 eye (*study eye*). Secondary: retina anatomy of the study eye, safety and tolerability, PK, PD.Exploratory: Best-corrected visual acuity, SD-OCT and retina anatomy of the…

Comparison of monocular implantation of the Acrysof Toric T2 intraocular lens with a standard monofocal intraocular lens in subjects with cataracts and low corneal astigmatism

- Analyse the effect of the toric T2 intraocular lens on quality of vision, compared to a standard monofocal intraocular lens. - Analyse the satisfaction of patients with their visual acuity with the toric T2 intraocular lens, compared to a standard…

An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution.

A new formulation of DuoTrav® eye drops, called DuoTrav APS, in which, the preservative (BAC) has been replaced by a new preservative called POLYQUAD has been developed. POLYQUAD is expected to be better tolerated in the eye, especially for the…

Vitamin D treatment effect on retinal nerve fiber loss after optic neuritis

Primary objective:- To determine whether high dose vitamin D treatment in optic neuritis can reduce axonal loss as measured by OCT. Secondary objectives: - To investigate whether the occurrence of a second attack (defining clinically definite MS) is…

Crowding in children with visual impairment: The effect of a magnifier on near visual acuity

This study has two major goals. The first goal of this study is to evaluate whether the disabilitating effects of crowding can be reduced by the use of a magnifier early in life. The second goal is to investigate motor and visual development of…

Navilas* laser versus classic frequency doubled Nd-YAG (532 nm) laser therapy for diabetic macular edema. A randomized study analyzing the effect on central visual function.

To study the impact of laser photocoagulation on the parafoveal visual field in a previously untreated population of patients with DME.

An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)

• To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects with LCA or RP caused by RPE65 or LRAT gene mutations who have been treated previously with a single 7-day course of QLT091001 in…

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious Intermediate-, Posterior-, or Pan-uveitis

The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week (eow) subcutaneously (SC) starting at Week 1 compared with placebo as maintenance therapy in subjects…